NCT03818880

Choroidal Response to Novel Spectacle Lens to Control Myopia Progression

A Sub-Study to Assess the Choroidal Response to Novel Spectacle Lens to Control Myopia Progression (CHERRY)

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: SightGlass Vision, Inc. · Industry
• Sex: All
• Age: 6 Years – 10 Years
• Healthy volunteers: Accepted

Summary

Diurnal variations in the thickness of the choroid have been reported in the literature, and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression.

Detailed description

Diurnal variations in the thickness of the choroid have been reported in the literature , and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression. SightGlass Vision, Inc is conducting a multi-site, randomized, controlled, interventional study to confirm the efficacy and safety of spectacle lenses designed to inhibit the progression of myopia by reducing image contrast in peripheral vision. CORE is participating as a clinical site in this three year study which aims to compare changes in ocular length and cycloplegic auto-refraction in children randomised to wear one of either two test or one control spectacle lens designs; the CPRO-1802-001 (Cypress\_SG) study. The sponsor is interested in conducting choroidal thickness measurements only at CORE's site by inviting those participants who have already been found eligible for the CPRO-1802-001 study to participate in this parallel study.

Conditions

• Myopia, Progressive

Interventions

Type	Name	Description
DEVICE	Novel spectacle lens design	Spectacle lens to control progression of myopia

Timeline

• Start date: 2018-12-18
• Primary completion: 2022-04-21
• Completion: 2026-03-31
• First posted: 2019-01-28
• Last updated: 2024-12-20

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated device study